Navigation Links
LSTM begins £0.5 million malaria study in Burkina Faso
Date:2/3/2010

A new study led by LSTM will investigate whether long-term weekly iron and folic acid supplementation can reduce anaemia without increasing the risk of contracting malaria. The information provided by the study, based in Burkina Faso and running until 2014, will strengthen adolescent health services and develop effective preventative programmes for anaemia control in young women.

Young women who conceive during or shortly after adolescence may enter pregnancy with deficient iron stores due to their development and the onset of menstruation. This can be offset with iron supplementation but there is some evidence that this can increase the risk of contracting malaria. Many young women tend not to present at antenatal clinics until mid-pregnancy and are therefore unlikely to be protected from malaria at the most susceptible period in early pregnancy.

Professor Bernard Brabin, Head of LSTM's Child and Reproductive Health department, has secured a 0.5 million grant from the US National Institutes of Health, through support from the Bill & Melinda Gates Foundation, to test the hypothesis that iron supplementation in young women prior to conception and during early pregnancy results in reduced iron deficiency and anaemia in pregnancy without increasing malaria risk. The study is being conducted in partnership with the Centre Muraz in Burkina Faso and the Institute of Tropical Medicine in Antwerp.

Professor Brabin explained: "As young women who are pregnant for the first time are particularly susceptible to the risks of malaria in pregnancy, it is essential to assess the safety of long term weekly supplementation, an approach now recommended by the World Health Organization. Some fifty million pregnant women are at risk of malaria every year but there are only four published studies of the effects of iron treatments during pregnancy on the prevalence of both malaria and anaemia and none on malaria risks in early pregnancy."

The study will look at the differences in malaria parasite prevalence, the incidence of clinical malaria and the prevalence of iron deficiency and anaemia between two randomised groups, one receiving iron supplementation and the other a placebo. Qualitative studies will assess adherence to weekly iron supplementation. The subjects will be followed from enrolment through conception to their first antenatal visit and delivery. The trial will be conducted according to the principles of good clinical practice and wil be reviewed by Ethical Committees in the three partner countries.

Professor Brabin continued: "Once we have a definitive answer to whether supplementation is safe, we will be able to inform the way adolescent health services are promoted, with the aim to develop more effective preventative programmes for anaemia control in young women."


'/>"/>

Contact: Alan Hughes
a.p.hughes@liv.ac.uk
44-151-705-3308
Liverpool School of Tropical Medicine
Source:Eurekalert

Related biology news :

1. Study begins to reveal clues to the cause and progression of sepsis
2. U of M begins nations first clinical trial using T-reg cells from cord blood in leukemia treatment
3. DHS Begins Collecting 10 Fingerprints From International Visitors at Washington Dulles International Airport
4. UC San Diego begins trading greenhouse gas credits on Chicago Climate Exchange
5. DHS Begins Collecting 10 Fingerprints From International Visitors at Hartsfield-Jackson Atlanta International Airport
6. Exploration of lake hidden beneath Antarcticas ice sheet begins
7. DHS Begins Collecting 10 Fingerprints From International Visitors at Boston Logan International Airport
8. DHS Begins Collecting 10 Fingerprints From International Visitors at Chicago OHare International Airport
9. DHS Begins Collecting 10 Fingerprints From International Visitors at George Bush Houston Intercontinental Airport
10. DHS Begins Collecting 10 Fingerprints From International Visitors at San Francisco International Airport
11. DHS Begins Collecting 10 Fingerprints From International Visitors at Miami International Airport
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2016)... and LONDON , April 26, ... of EdgeVerve Systems, a product subsidiary of Infosys ... announced a partnership to integrate the Onegini mobile ...      (Logo: http://photos.prnewswire.com/prnh/20151104/283829LOGO ) ... customers enhanced security to access and transact across ...
(Date:4/14/2016)... TEL AVIV, Israel , April 14, 2016 /PRNewswire/ ... in Behavioral Authentication and Malware Detection, today announced the ... has already assumed the new role. Goldwerger,s ... for BioCatch, on the heels of the deployment of ... In addition, BioCatch,s behavioral biometric technology, which discerns unique ...
(Date:3/23/2016)... , March 23, 2016 ... erhöhter Sicherheit Gesichts- und Stimmerkennung mit Passwörtern ... (NASDAQ: MESG ), ein führender ... das Unternehmen mit SpeechPro zusammenarbeitet, um erstmals ... Finanzdienstleistungsbranche, wird die Möglichkeit angeboten, im Rahmen ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... - BIOREM Inc. (TSX-V: BRM) ("Biorem" or "the Company") announces ... Clean Technology Fund I, LP and Clean Technology Fund ... venture capital funds which together hold approximately 59% of ... as converted basis), that they have entered into an ... in Biorem to TUS Holdings Co. Ltd. ("TUS") (en.tusholdings.com) ...
(Date:6/27/2016)... ... 27, 2016 , ... Rolf K. Hoffmann, former senior vice ... University of North Carolina Kenan-Flagler Business School effective June 27. , ... with a focus on the school’s international efforts, leading classes and participating in ...
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial spectrophotometers and ... and the 6000i models are higher end machines that use the more unconventional z-dimension ... light beam from the bottom of the cuvette holder. , FireflySci has developed ...
(Date:6/23/2016)... , June 23, 2016 /PRNewswire/ - FACIT has ... Ontario biotechnology company, Propellon Therapeutics Inc. ... and commercialization of a portfolio of first-in-class WDR5 ... targets such as WDR5 represent an exciting class ... in precision medicine for cancer patients. Substantial advances ...
Breaking Biology Technology: